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previous cigar use (OR 3.44model 1, OR 2.05model 2, OR 2.67model 3), previous
alcohol use (OR 2.1 model 1), having friends (OR 3.87model 1, OR 2.74model 2)
and/or siblings (OR  3.18 model 1, OR  2.53 model 2, OR  2.86 model 3) that use
waterpipes, were significant predictors of waterpipe smoking. Perception of harm
equivalent to cigarettes ormorewas associatedwith less use (OROR 0.262model
2, OR  0.305 model 3). CONCLUSIONS: High rates of waterpipe smoking in both
gendersweredocumented, evenamongparticipants recognizing theassociatedharm.
Data suggests the importance of incorporating the predictors identified in future in-
tervention strategies.
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OBJECTIVES: To assess the association between use of inhaled tobramycin andmor-
tality in patientswith cystic fibrosis and chronic Pseudomonas aeruginosa (PA) infection.
METHODS: Patients aged 6 years with FEV1 %-predicted 25-75% and chronic PA
infection were identified from the United States Cystic Fibrosis Foundation’s Patient
Registry (1996 –2008). Patients were followed from the first year in which all these
criteria weremet (index year) to death or end of continuous data availability. Longitu-
dinal logistic regression was used to assess the association between current-year re-
porteduseof inhaled tobramycin and subsequent-yearmortality,with adjustment for
demographics, comorbidities, reported use of dornase alpha or high-dose ibuprofen,
FEV1 %-predicted and medical resource use. RESULTS: Among 12,740 patients meet-
ing inclusion criteria, 2,538 deaths were observed during a median follow-up of 6
years. At index, mean age was 22 years, mean FEV1 %-predicted was 62%, 16% were
underweight for age and 64% reported inhaled tobramycin use. After regression ad-
justment, use of tobramycin inhalation solutionwas associatedwith a significant 21%
reduction in the odds of subsequent yearmortality (odds ratio: 0.79, P 0.001). Use of
dornase alfa was similarly associated with reduced mortality (odds ratio: 0.85, P 
0.005). In the same regression model, underweight for age, cystic fibrosis-related dia-
betes, female gender,worse lung function and cultures positive for PAor Burkholderia
cepacia complex, amongmultiple other patient characteristics, were associated with
significantly increased mortality. Adjusted mortality rates for patients reporting to-
bramycin inhalationsolutionuse inall vs.noneof the follow-upyearswere1.3vs. 2.1%
at 2 years, 5.2 vs. 8.0% at 5 years and 9.9 vs. 15.0% at 10 years. CONCLUSIONS: After
adjusting for clinical status and other treatments, inhaled tobramycin use was asso-
ciated with significantly reduced mortality among cystic fibrosis patients meeting
recommended criteria for inhaled tobramycin use.
PRS8
DISEASE PROGRESSION IN CYSTIC FIBROSIS — SYNTHESIS OF SURVIVAL
EVIDENCE
Becker CC1, Vieira MC2, Harrow B1, Liou TG3, Jansen JP2
1Vertex Pharmaceuticals Incorporated, Cambridge, MA, USA, 2MAPI Values, Boston, MA, USA,
3University of Utah, Salt Lake City, UT, USA
OBJECTIVES: Cystic fibrosis (CF) is the most common fatal genetic disease in Cau-
casians with an annual birth incidence of 1:2,500. CF is ultimately fatal due to
progressive dysfunction of organs such as lung and pancreas. Improved knowledge
of the ion channel defect that causes the disease has raised the possibility of
treating the cause of CF. To develop an understanding of how different factors
contribute to disease progression, published evidencewas used to develop amodel
of mortality as a function of age and prognostic factors. METHODS: A systematic
literature review of CF disease progression was performed in Medline and Embase.
Prospective and retrospective cohort studies as well as case-control studies were
included if they reported mortality jointly with prognostic factors. Covariates of
interest included gender, lung function, weight-for-age, pancreatic sufficiency, di-
abetes, lung microflora and number of acute exacerbations. Results were synthe-
sized by means of Bayesian meta-analysis techniques. RESULTS: Seven studies
provided data on over 22,000 patients, which helped to develop a survival model
based on age and the prognostic factors. Survival over time was described with a
Gompertz model with its scale parameter affected by birth cohort, gender, lung
function, infection with Burkholderia cepacia and Staphylococcus aureus, diabetes,
number of exacerbations, and pancreatic sufficiency. The shape parameter was
assumed to be only affected by birth cohort. CONCLUSIONS: A survival model was
developed that estimates remaining life expectancy for CF patients based on their
clinical characteristics. Lung function is the primary determinant of life expec-
tancy, but several other factors have major impact. Of these, lung function and
acute exacerbations are direct targets of intervention, while infections may be
prevented or treated, and diabetes and pancreatic insufficiency may be methodi-
cally managed to potentially improve survivorship.
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OBJECTIVES: The purpose of the study is to compare the costs, cost drivers and
prevalence of COPD-related hospitalizations for Hispanic andWhite patients in US
hospitals. METHODS: A retrospective cohort of COPD related hospitalized patient
discharges in 2007 were identified from a nationally representative database of
over 500 hospitals. Subjects were included if they had primary diagnosis code for
COPD (ICD9-CM 491, 492 or 496), Hispanic or White race and of age 18. COPD
related discharge rates for US population were calculated using hospital discharge
data and projection weight methodology and were further stratified by race. His-
panic discharges were matched (1:3) to comparison group of White discharges by
sex, severity score, and 5-year age ranges for an analysis of mortality and mean
costs. Unadjustedmortality andmean costs were compared by race, and cost driv-
ers were identified using a gamma generalized linear model incorporating gener-
alized estimating equations to account for the non-independent matched
discharges. RESULTS: The calculated national estimates for COPD related dis-
charges were: 490,636 total discharges including 71.4%White and 2.6% (n 12,661)
Hispanic. The study population was comprised of a cohort of 1,644 Hispanic dis-
charges meeting the inclusion criteria and a matched group of 4,932 White dis-
charges. For matched discharges the mortality rate for Whites was significantly
higher than Hispanics (1.4% White vs. 0.23% Hispanic, p.006). Hispanics had sig-
nificantly higher (P.01) unadjustedmean total patient costs ($7,356) versuswhites
($6,748), with no difference in length of stay. Hispanic hospitalizations had signif-
icantly higher costs than White hospitalizations (P  .0001). Regression analysis
identified the significant cost drivers: severity score, Hispanic race, LOS, ICU days,
urban hospital, and teaching hospital, (all with P  .025). CONCLUSIONS: As the
Hispanic population and COPD prevalence continue to rise; differences in burden,
cost, cost-drivers and treatment patterns in Hispanics warrant additional investi-
gation in an attempt to target services and reduce the burden.
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OBJECTIVES: In Nicaragua, 30% of current morbidities are associated with tobacco
smoking. Tobacco control policy measures have been initiated in this Central Ameri-
can country, however thepopulationdoesn’t have full consciousness of the long-term
consequences of tobaccouse. The aimof this studywas to compare thedirectmedical
costs of smoking cessation therapies with varenicline, nicotine replacement therapy
(NRT) and unaided cessation in Nicaragua over two time-horizons: 10 and 20 years.
METHODS: The current annual costs of chronic obstructive pulmonary disease
(COPD), lungcancer, coronaryheartdisease (CHD)andstrokewereestimatedbasedon
the current annual incidence for each disease using one public hospital databases
(Hospital Lenin Fonseca, 2010). The Benefits of Smoking Cessation on Outcomes (BE-
NESCO) simulationmodel was used to obtain the projected direct costs for each strat-
egy. An adult cohort (n3,639,948) fromNicaraguawas used and the assessment was
conducted using the healthcare payer’s perspective. Costs were discounted at 3% an-
nually. Probabilistic sensitivity analyses were conducted using Monte Carlo second
order approach. RESULTS: Varenicline is associatedwith the highest healthcare cost-
savings compared with the other two alternatives at 10 and 20 years. Results at 10
years, showed that varenicline would save US$126,599 and US$188,582 against NRT
and unaided cessation, respectively. In 20 years, savings would be US$3,609,463 and
US$5,971,233 against NRT and unaided cessation. The results of probabilistic sensitiv-
ity analyses support these findings. CONCLUSIONS: The use of a smoking cessation
therapy with varenicline would generate savings in the long-term in almost 6million
dollars to Nicaragua’s healthcare institutions.
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OBJECTIVES: To estimate the direct medical costs and indirect costs of food-in-
duced allergic reactions and anaphylaxis in the U.S. METHODS: Costs were esti-
mated with a bottom-up approach from a societal perspective: the average cost of
illness per patientwas calculated andmultiplied by reported prevalence estimates.
Patients with an inpatient admission, emergency department admission, office-
based physician visit, or outpatient visit for a food-induced allergic reaction were
identified from a list of federally administered 2006 and 2007 databases by using
ICD-9 codes. Indirect costs were quantified by estimating the lost productivity, in
terms of lost earnings due to absenteeism and mortality, of patients or caregivers.
Sensitivity analyses were conducted to measure the robustness of the estimates.
RESULTS: For 2007, direct medical costs were $225 million and indirect costs were
$115million. Office visits accounted for 52.5% of costs, and the remainder was split
between emergency visits (20%), inpatient hospitalizations (11.8%), outpatient vis-
its (3.9%), ambulance runs (3%), and epinephrine devices (8.7%). Simulations from
probabilistic sensitivity analyses suggested mean direct medical costs were $307
million and indirect costswere $203million.CONCLUSIONS:The economic burden
of allergic reactions due to food and anaphylaxis was an estimated half a billion
dollars in 2007. Ambulatory visits accounted for more than one half of costs.
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